Published 2 days ago • loading... • Updated 10 hours ago
Can Oral Semaglutide Reduce Alcohol Use? CU Anschutz Clinical Trial Shows Fewer Heavy Drinking Days
In an eight-week trial of 50 adults, oral semaglutide reduced heavy drinking days, cravings and alcohol-related problems, researchers said.
A study published today in The American Journal of Psychiatry reports that oral semaglutide reduces heavy drinking in adults with Alcohol Use Disorder. Researchers at Anschutz conducted the eight-week clinical trial.
Since 2006, no new medications have been FDA-approved for AUD, a chronic condition affecting millions. This lack of options creates urgent need for new therapeutic approaches.
In an eight-week study involving 50 adults, participants receiving oral semaglutide showed reduced alcohol consumption, lower cravings, and improved drinking risk levels. The National Institute on Alcohol Abuse and Alcoholism funded the research.
Joseph Schacht, PhD, an associate professor at Anschutz, noted that identifying new treatments is critical because many people do not respond to current therapies. Even modest reductions in heavy drinking can improve stability and quality of life.
Anschutz and partner institutions are planning to conduct larger trials soon to evaluate the medication further. Oral semaglutide could represent a new treatment option for AUD, particularly for those who have not benefited from existing medications.